Laura Bolaño G.

MD @uninorteco 🇨🇴 Internista- oncóloga clínica @incmnszmx, UNAM 🇲🇽; Oncologa torácica, @incanmx, UNAM🇲🇽; Master Neop. Tx, UAX 🇪🇸 📍Clínica Portoazul 🏥

[Yakup Ergün @dr_yakupergun]

DCIS Management in 2026: A Practical NCCN-Based Algorithm for Clinicians

(AI-assisted infographic. Content reviewed)

[Oscar Arrieta @ogarrieta]

¿Neoadyuvancia o tratamiento perioperatorio?

Una revisión que analiza la evidencia más reciente sobre inmunoterapia y biomarcadores en el cáncer de pulmón de células no pequeñas, con la participación del @drcoronacruz y cols.

[The Lancet @TheLancet]

Triple-negative breast cancer is the most aggressive form of the disease, and it often spreads to the brain. Treatment options remain limited, and outcomes for patients are often poor.

A Review in @TheLancetOncol draws together the latest evidence to provide a roadmap for unmet clinical needs: https://t.co/z389XnqKN9

[European Urology Oncology @EurUrolOncol]

➡️ Monday Morning Mention!

➡️ PSMA PET in Prostate Cancer: Clinical Value, Access Challenges, and Priorities for Implementation BY Arthur Peyrottes, Léa Turpin, Laura Fernández Hernández, and Morgan Rouprêt
https://t.co/DQCyeK6awz

➡️ We thank the authors for trusting EUO to publish your work.

@ArthurPeyrottes

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[Colorectal Cancer Alliance @CCAlliance]

What role do biomarkers, immunotherapy, and targeted therapies play in modern colorectal cancer treatment? Explore the latest evidence with Drs. Scott Kopetz (@skopetz), Cathy Eng (@CathyEngMD), and Marwan Fakih (@mgfakih) in this @PeerView on-demand activity: https://t.co/zeLxRTIkkU

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 PARP-i in metastatic hormone-sensitive #ProstateCancer🚨

📜#TALAPRO3 out in @NEJM

In HRR-altered mHSPC, adding talazoparib to enzalutamide + ADT:

✅ Reduced risk of progression/death by 52% (HR 0.48)
📈 3-year rPFS: 77% vs 56%
⏳ OS trend favors combination (HR 0.77), but immature.
⚠️ More anemia (Grade ≥3: 51%).

👉Potential new standard for a biomarker-selected population

@neerajaiims @urotoday @renalandurology @UrologyTimes @UroOnc @SUO_YUO @PCFnews

🔗https://t.co/YXCiIWPwqg

[Yakup Ergün @dr_yakupergun]

Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management

Great review👇

https://t.co/06qiAyBqWA

[Stephen V Liu, MD @StephenVLiu]

Report on time to symptomatic progression from phase III MARIPOSA study in EGFR mutant NSCLC available. Median was 43.6m with 1L amivantamab + lazertinib compared to 29.3m with osimertinib (HR 0.69). TTSP strongly correlated with PFS and OS.

https://t.co/bBYvXSNIOd

[NEJM @NEJM]

Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEYNOTE-B15/EV-304 trial results: https://t.co/5Y1ZnAvBFK

Editorial: A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? https://t.co/Jkuc0w9hhV

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Internal guidelines from @DanaFarber for omission of sentinel lymph nodes in low-risk breast cancer @ASCOPres

[Enrique Grande @drenriquegrande]

⚡️ Adjuvant pembrolizumab + belzutifan vs pembrolizumab alone in high-risk ccRCC after nephrectomy (LITESPARK-022):

DFS: HR 0.72 (95% CI 0.59–0.87; p<0.001)
24-month DFS: 80.7% vs 73.7%
First phase 3 trial in RCC to show DFS benefit of a combination vs an active IO comparator.

Grade ≥3 AEs 52.1% vs 30.2%. OS immature.

https://t.co/tG7YDywaG2

#KidneyCancer @NEJM

[Thor Halfdanarson @OncoThor]

And it is on again!

The Annual Mayo Clinic Oncology Review. First up is @rleonferre talking about HER2+ and triple negative breast cancer. As expected, a superb presentation, packed with pearls!

A full day ahead, packed with exciting updates. Join us next year!

@MayoCancerCare @MayoHemeOnc @MayoMedEd

[Gabriel Puche, MD/PhD @gabi_puchepalao]

🦴 TRATAMIENTO DE LA OSTEOPOROSIS EN 2026

Si solo recuerdas una cosa para tu práctica clínica, que sea esta:

👉 El tratamiento NO depende del T-score.
👉 Depende del RIESGO DE FRACTURA.

Abro hilo 🧵👇

[Paolo Tarantino @PTarantinoMD]

Results from HER2CLIMB-04 show that combining T-DXd with tucatinib does not lead to higher efficacy than T-DXd monotherapy. Follows the disappointing results of HER2CLIMB-02 (T-DM1 + tuc). Tucatinib stabilizes HER2 on the membrane: bad partner for ADCs? https://t.co/L3o8mddLjL

[Dr. Sachin Hingmire @dr_hingmire]

Molecular Oncology in Clinics

A deeper dive into another critical DNA repair pathway—the Homologous Recombination Repair (HRR) pathway.

[Karamvir Yadav @K_Yadavir]

Updated Asian Consensus Guidelines 2025 for GIST are here.

Key practice-changing updates:
🧬 Molecular profiling before systemic therapy
💊 Precision treatment based on KIT/PDGFRA/NTRK/BRAF
🔪 R0 surgery without tumor rupture remains critical
📈 3 years of adjuvant imatinib remains standard for high-risk disease
🎯 Ripretinib preferred as 4th-line therapy

A concise visual summary for busy clinicians.

#GIST #Oncology #MedOnc #PrecisionOncology #CancerResearch #GIOncology #MedTwitter #OncoTwitter @OncoDailyGI

[Yakup Ergün @dr_yakupergun]

The SERENA-6 PFS2 results were presented at #ASCO26 . The full-text is now published, but the OS data remain immature. The current curves do not show a clear separation. Whether an OS benefit will emerge with longer F/U remains an open question.

https://t.co/T1HjdsUMtX

[MGBCI Breast Oncology @MGBCI_BreastOnc]

🚨 New in @JCOOP_ASCO from @maxwellRlloyd et al. 👇
Review of the evidence for emerging ER-targeted monotherapies and combination strategies across metastatic and curative-intent settings, addressing key questions on treatment selection and sequencing

🔗 https://t.co/cwuUBxzeaj

[Dr Rupam Manna MD @DrRupamOncology]

🧬 Not all hereditary colorectal cancers are the same—but each has a unique prevention strategy.

From Lynch syndrome to FAP, MAP, PJS, JPS, PTEN, and Serrated Polyposis Syndrome, recognizing the syndrome allows timely surveillance and can prevent colorectal cancer before it develops.

��� High-yield takeaway:
✅ FAP → Nearly 100% lifetime CRC risk without colectomy.
✅ Lynch syndrome → 40���80% lifetime risk, reduced with intensive colonoscopic surveillance and appropriate risk-reduction strategies.

Early identification + genetic counseling + tailored surveillance = Cancer prevention in action.

#ColorectalCancer #LynchSyndrome #FAP #HereditaryCancer #CancerGenetics #PrecisionOncology #GIOncology #MedicalOncology #CancerPrevention #Colonoscopy #GeneticCounseling #OncologyEducation #MedEd #FOAMed #CancerConcepts #DrRupamOncology

[Stephen V Liu, MD @StephenVLiu]

Phase III ELEVATE trial @NEJM for pts with resected stage IB to IIIB ALK+ NSCLC after adjuvant chemo randomized to ensartinib vs placebo x 2y (n=274). In stage II-III, 2y DFS 86.4% vs 53.5% (HR 0.20). Molecular testing for early stage NSCLC is critical!

https://t.co/6wQSu17deh